7-143321841-G-A

Variant summary

Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PP3_StrongPP5_Very_Strong

The NM_000083.3(CLCN1):​c.689G>A​(p.Gly230Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000279 in 1,614,072 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).

Frequency

Genomes: 𝑓 0.000020 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000029 ( 0 hom. )

Consequence

CLCN1
NM_000083.3 missense

Scores

17
1
1

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:11O:2

Conservation

PhyloP100: 8.19
Variant links:
Genes affected
CLCN1 (HGNC:2019): (chloride voltage-gated channel 1) The CLCN family of voltage-dependent chloride channel genes comprises nine members (CLCN1-7, Ka and Kb) which demonstrate quite diverse functional characteristics while sharing significant sequence homology. The protein encoded by this gene regulates the electric excitability of the skeletal muscle membrane. Mutations in this gene cause two forms of inherited human muscle disorders: recessive generalized myotonia congenita (Becker) and dominant myotonia (Thomsen). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 14 ACMG points.

PM1
In a transmembrane_region Helical (size 17) in uniprot entity CLCN1_HUMAN there are 7 pathogenic changes around while only 0 benign (100%) in NM_000083.3
PP3
MetaRNN computational evidence supports a deleterious effect, 0.968
PP5
Variant 7-143321841-G-A is Pathogenic according to our data. Variant chr7-143321841-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 17532.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr7-143321841-G-A is described in Lovd as [Pathogenic]. Variant chr7-143321841-G-A is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
CLCN1NM_000083.3 linkuse as main transcriptc.689G>A p.Gly230Glu missense_variant 5/23 ENST00000343257.7 NP_000074.3
CLCN1NR_046453.2 linkuse as main transcriptn.791G>A non_coding_transcript_exon_variant 5/22

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
CLCN1ENST00000343257.7 linkuse as main transcriptc.689G>A p.Gly230Glu missense_variant 5/231 NM_000083.3 ENSP00000339867 P4

Frequencies

GnomAD3 genomes
AF:
0.0000197
AC:
3
AN:
152254
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000120
AC:
3
AN:
251000
Hom.:
0
AF XY:
0.00
AC XY:
0
AN XY:
135704
show subpopulations
Gnomad AFR exome
AF:
0.0000616
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000176
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000287
AC:
42
AN:
1461818
Hom.:
0
Cov.:
33
AF XY:
0.0000316
AC XY:
23
AN XY:
727202
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000378
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.0000197
AC:
3
AN:
152254
Hom.:
0
Cov.:
33
AF XY:
0.0000134
AC XY:
1
AN XY:
74380
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000294
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000329
Hom.:
0
Bravo
AF:
0.0000227
ExAC
AF:
0.0000165
AC:
2
EpiCase
AF:
0.0000545
EpiControl
AF:
0.00

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:11Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:5
Pathogenic, criteria provided, single submitterclinical testingAthena DiagnosticsJan 09, 2023The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant is associated with autosomal dominant myotonia congenita in most families (PMID: 10533075, 8857727, 7981750, 18220014, 10467912, 23516313), however, it has also been associated with autosomal recessive myotonia congenita (PMID: 8857733, 23516313). Assessment of experimental evidence suggests this variant results in abnormal protein function. (PMID: 9122265, 8112288) -
Pathogenic, criteria provided, single submitterclinical testingClinical Genetics Laboratory, Skane University Hospital LundMay 30, 2023- -
Pathogenic, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicSep 25, 2020PS3, PS4, PP1, PP3, PP4 -
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityOct 17, 2023- -
Pathogenic, criteria provided, single submitterclinical testingGeneDxMar 16, 2020Reported previously in multiple unrelated families with myotonia congenita, most often in association with autosomal dominant inheritance (George et al., 1993; Meyer-Kleine et al., 1995).; Reported in a family exhibiting autosomal dominant inheritance, at least one carrier of G230E variant was reported to be clinically unaffected in adulthood, although EMG revealed subclinical myotonia (Meyer-Kleine et al., 1995).; Published functional studies have demonstrated that the Gly230 residue resides within the chloride channel pore and the G230E variant dramatically alters pore properties (Fahlke et al., 1997); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 10467912, 10533075, 15786415, 23739125, 28427807, 7981750, 8857733, 10720929, 11933197, 12390967, 18220014, 24349310, 18263754, 19570891, 9122265, 8857727, 8533761, 20301529, 29424939, 29606556, 31692161, 32670189) -
Congenital myotonia, autosomal recessive form;C2936781:Congenital myotonia, autosomal dominant form Pathogenic:2Other:1
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 26, 2024This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 230 of the CLCN1 protein (p.Gly230Glu). This variant is present in population databases (rs80356700, gnomAD 0.007%). This missense change has been observed in individual(s) with autosomal dominant myotonia congenita (PMID: 7981750, 18220014). It has also been observed to segregate with disease in related individuals. This variant is also known as Gly180Glu. ClinVar contains an entry for this variant (Variation ID: 17532). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CLCN1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects CLCN1 function (PMID: 8112288, 9122265). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsMar 31, 2022- -
not provided, no classification providedphenotyping onlyGenomeConnect - Invitae Patient Insights Network-Variant interpreted as Pathogenic and reported on 03-09-2020 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
Congenital myotonia, autosomal dominant form Pathogenic:2
Pathogenic, no assertion criteria providedliterature onlyOMIMMar 18, 1997- -
Pathogenic, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaMay 12, 2021The CLCN1 c.689G>A (p.Gly230Glu) variant is a missense variant. Across a selection of the available literature, the p.Gly230Glu variant has been identified in a heterozygous state in at least eight probands and 12 affected family members with autosomal dominant myotonia congenita from eight families showing segregation with the disorder (George et al. 1993; Koty et al. 1996; Brugnoni et al. 1999, Chang et al. 2015). Expressivity of the disease associated with the variant is variable, Chang et al. (2015) reported the variant to be present in a heterozygous state in one 17-year-old female asymptomatic carrier in a family with two affected individuals. The p.Gly230Glu variant was also reported in a compound heterozygous state with a stop gained variant in one individual, in whose family both the mother and sibling were noted to be carriers of the p.Gly230Glu variant and asymptomatic (Zhang et al. 1996). The p.Gly230Glu variant is reported at a frequency of 0.000012 in the total population of the Genome Aggregation Database (version 2.1.1) in a region of good sequence coverage. Heterologous expression of the p.Gly230Glu variant in Xenopus oocytes suggest the variant exerts a dominant negative effect on the channel. Additional work in mammalian cell lines showed that the p.Gly230Glu variant induced changes in ion selectivity relative to the wildtype protein (Steinmeyer et al. 1994; Fahlke et al. 1997). Based on the collective evidence and application of the ACMG criteria, the p.Gly230Glu variant is classified as pathogenic for the autosomal dominant form of myotonia congenita. -
CLCN1-related disorder Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesFeb 12, 2024The CLCN1 c.689G>A variant is predicted to result in the amino acid substitution p.Gly230Glu. This variant has been previously reported in multiple families with myotonia congenita, primarily in association with autosomal dominant inheritance (George et al. 1993. PubMed ID: 7981750; Meyer-Kleine et al. 1995. PubMed ID: 8533761; Chang et al. 2007. PubMed ID: 18220014). Functional studies suggested that the p.Gly230Glu substitution dramatically altered the pore properties of CLCN1 (Fahlke et al. 1997. PMID: 9122265). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD. This variant is interpreted as pathogenic. -
Congenital myotonia, autosomal recessive form Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpJun 27, 2023Variant summary: CLCN1 c.689G>A (p.Gly230Glu) results in a non-conservative amino acid change located in the TM1 domain (Sutterlin_2022) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251000 control chromosomes. c.689G>A has been reported in the literature as a heterozygous genotype or as a compound heterozygous genotype in multiple individuals affected with Congenital Myotonia (example, Sutterlin_2022; Horga_2013). These data indicate that the variant is very likely to be associated with disease. At least two publications report experimental evidence evaluating an impact on protein function (example, Fahlke_1997, Steinmeyer_1994). The most pronounced variant effect results in altered pore properties of the muscle chloride channel (Fahle_1997) and destroy normal channel activity while exerting a dominant negative effect of wild-type channels (Steinmeyer_1994). The following publications have been ascertained in the context of this evaluation (PMID: 9122265, 23516313, 8112288, 34529042). Seven submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Batten-Turner congenital myopathy Other:1
not provided, no classification providedliterature onlyGeneReviews-Associated with autosomal recessive and autosomal dominant mode of inheritance -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
1.0
BayesDel_addAF
Pathogenic
0.45
D
BayesDel_noAF
Pathogenic
0.58
CADD
Pathogenic
30
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.96
.;D
Eigen
Pathogenic
0.99
Eigen_PC
Pathogenic
0.88
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Pathogenic
1.0
D;D
M_CAP
Pathogenic
0.69
D
MetaRNN
Pathogenic
0.97
D;D
MetaSVM
Pathogenic
0.92
D
MutationAssessor
Pathogenic
4.4
.;H
MutationTaster
Benign
1.0
A
PrimateAI
Pathogenic
0.84
D
PROVEAN
Pathogenic
-7.8
.;D
REVEL
Pathogenic
0.98
Sift
Pathogenic
0.0
.;D
Sift4G
Pathogenic
0.0
.;D
Polyphen
1.0
.;D
Vest4
0.96
MVP
0.99
MPC
0.85
ClinPred
1.0
D
GERP RS
5.0
Varity_R
0.98
gMVP
0.98

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs80356700; hg19: chr7-143018934; COSMIC: COSV100577570; API